Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333177 · ClinicalTrials.gov registry record · Phase 4
Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
NCT00333177: Completed Phase 4 study, sponsored by University of California, Los Angeles.
NCT00333177 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 92 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00333177, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia.
Primary Outcome
Values presented here are the changes in MCCB Overall Composite T scores from baseline to 12 months, with higher values representing better outcome. Raw test scores are used to generate T-scores and then the seven MCCB domains are combined to generate an Overall Composite T score. MCCB Overall Composite T scores have a mean in the general population of 50 with a standard deviation of 10. Thus, a positive change of 5 T scores is an improvement of half a standard deviation.
Interventions
- BEHAVIORAL Cognitive remediation training (CT)
- BEHAVIORAL Healthy behavior training (HBT)
- DRUG Risperidone, administered orally (Oral Ris)
- DRUG Risperidone, administered via injection (RLAI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2006-03 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
What the finished NCT00333177 record still lists
NCT00333177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 4 interventions - of which Cognitive remediation training (CT) is the first listed.
NCT00333177 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00333177 about?
NCT00333177 is a clinical study titled "Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia". This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia.
What is the current status of trial NCT00333177?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2006-03. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00333177?
The interventions under investigation include: Cognitive remediation training (CT) (BEHAVIORAL), Healthy behavior training (HBT) (BEHAVIORAL), Risperidone, administered orally (Oral Ris) (DRUG), Risperidone, administered via injection (RLAI) (DRUG).
Who is sponsoring clinical trial NCT00333177?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00333177's enrollment target sits among peer trials
92 876th of 2000 higher than 1,117 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia